A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: required (1000), wanted (88), hunted (8)

WRES report and action plan 2023

Description
Workforce Race Equality Standard Annual Report 2023 1 Table of Contents Executive Summary................................................................................................................................. 3 Introduction ............................................................................................................................................ 5 WRES Data Submission 2023 .................................................................................................................. 5
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/WRES-report-and-action-plan-2023.pdf

Avelumab-Axitinib

Description
Chemotherapy Protocol RENAL CELL AVELUMAB-AXITINIB Regimen • Renal Cell - Avelumab-Axitinib Indication • Unresectable locally advanced or metastatic renal cell carcinoma (RCC
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Axitinib-Avelumab.pdf

Endometrial Carboplatin-Cisplatin-PaclitaxelRT(21day)

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CARBOPLATIN (AUC5)-CISPLATIN-PACLITAXEL RT Regimen • Endometrial-Carboplatin (AUC5)-Cisplatin-Paclitaxel RT Indication • The treatment of endometrial
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Endometrial-Carboplatin-Cisplatin-Paclitaxel-RT-21day.pdf

Transient ischemic attack (TIA) - patient information

Description
Transient ischemic attack (TIA) Information for patients You have been given this booklet because you have been referred to the TIA
Url
/Media/UHS-website-2019/Patientinformation/Brain-and-spine/Transient-ischemic-attack-TIA-685-PIL.pdf

Telephoning Results and Ranges

Description
University Hospital Southampton NHS Foundation Trust LABORATORY MEDICINE G3.2 Telephoning Results and Ranges G3.2 3.2
Url
/Media/UHS-website-2019/Docs/Services/Pathology/Lab-med/Telephoning-Results-and-Ranges.pdf

Cytarabine(SC)-Venetoclax

Description
Chemotherapy Protocol Acute Myeloid Leukaemia CYTARABINE (SC) - VENETOCLAX Regimen  AML – Cytarabine (SC) -Venetoclax Indication  Newly diagnosed acute myeloid leukaemia (AML).  Patient
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/CytarabineSC-Venetoclax.pdf

Workforce Race Equality Standard Annual Report 2022

Description
Workforce Race Equality Standard - Annual Report 2022 Table of Contents Executive Summary 3 Introduction 5 WRES Data Submission 2022 6 Indicato
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/Workforce-Race-Equality-Standard-Annual-Report-2022.docx

Atezolizumab-Bevacizumab

Description
Chemotherapy Protocol Hepatocellular Cancer ATEZOLIZUMAB-BEVACIZUMAB Regimen  HCC-Atezolizumab-Bevacizumab Indication  Atezolizumab in combination with bevacizumab for the first-line systemic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Atezolizumab-Bevacizumab.pdf

UHS Our People Strategy 2022 - 2026

Description
OUR PEOPLE STRATEGY 2022 to 2026 CONTENTS 05 Foreword by Steve Harris – chief people officer 06 Our strategic framework 07 Always
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Plans-and-strategies/UHS-Our-People-Strategy-2022-2026.pdf

Leg amputation - patient information

Description
Information about leg amputation surgery, performed as an absolute last resort for poor blood flow to your leg, or a serious
Url
/Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Leg-amputation-1661-PIL.pdf
501 to 510 of 571
Previous … 49 50 51 52 53 … Next